Dr. Jeffrey R. Schriber, MD

Dr. Schriber practices at City of Hope Cancer Center Phoenix in Goodyear, Arizona, part of City of Hope.

Dr. Schriber's NPI, 1851369821, was assigned on March 8, 2006. Dr. Schriber graduated from University of Toronto Faculty of Medicine in 1986. Dr. Schriber holds Arizona license 25423.

Dr. Schriber's primary practice is City of Hope Cancer Center Phoenix, at 14200 West Celebrate Life Way, Goodyear, AZ 85338 in Maricopa County. The practice phone is (623) 207-3000.

Dr. Schriber's primary practice is City of Hope Cancer Center Phoenix in Goodyear, Arizona, part of City of Hope. The medical group on file is City of Hope. Dmand AI also links Dr. Schriber to 1 more medical group, named with a free account. Dr. Schriber's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schriber practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Schriber's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Schriber is board certified in hematology by the Canada's Royal College of Physicians and Surgeons. Dmand AI has Dr. Schriber's licenses on file in 6 states: Arizona, California, New Mexico, Idaho, Oklahoma and New York.

Dmand AI lists chronic anemia, chronic leukemia, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Schriber treats.

CMS data shows 278 Medicare services from Dr. Schriber across 3 procedure codes in 2024, all of them office visits, for 83 Medicare patients. Medicare paid $18,970 for them.

CMS counts 83 Medicare patients who saw Dr. Schriber in 2024. The largest group is 65 to 74, with 45 patients. 73% of them have high cholesterol, and 72% have high blood pressure. Their average risk score is 2.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schriber's median patient age at 71, with 46% women.

In 2024, Dr. Schriber wrote 299 Medicare Part D claims for 43 patients. 65% of them were for generic drugs. CMS names the drug for 161 of them, across 9 drugs with 11 or more claims each, at $1,370,240 in total drug cost. In 2023, CMS named 164 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Schriber for performance year 2024, reported as part of a group. Dr. Schriber accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schriber as offering telehealth.

Dmand AI links 38 papers to Dr. Schriber, published from 2007 to 2022. 2015 was the busiest year, with 3. The most frequent topics are Hematopoietic Stem Cell Transplantation, Transplantation, Homologous and Bone Marrow Transplantation. Dr. Schriber has published most often in Biol Blood Marrow Transplant. Dr. Schriber's most frequent co-authors are Robert Stuart Negrin, MD, Parameswaran N. Hari, MD and Joseph C. Alvarnas, MD.

Dmand AI links Dr. Schriber to 5 clinical trials, 2 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Anemia, Aplastic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive and Multiple Myeloma. Open Payments lists research payments to Dr. Schriber that name 2 trials.

CMS Open Payments shows 1,360 general payments to Dr. Schriber from 37 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 65% of the total. Seagen Inc. paid the most, $203,495. It also lists 4 research payments totaling $4,807 from 2018 to 2025, naming 2 clinical trials.

Dr. Schriber graduated from University of Toronto Faculty of Medicine in 1986. Dr. Schriber is a member of ACP, American Society for Blood and Marrow Transplantation, ASCO, ASH, Canadian Medical Association and Royal College of Physicians and Surgeons.

Dr. Schriber is in network with 18 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.